New studies reportedly suggest lasting immunity to COVID-19 even in mild cases


Experts are voicing optimism that the body provides lasting COVID-19 immunity in those who have recovered from even a mild case following a series of new studies.
Scientists have recently been seeing "encouraging signs of strong, lasting immunity" to COVID-19, including in those who only had mild symptoms of the coronavirus, as antibodies that fight against the virus, and B cells and T cells that recognize it, "appear to persist months after infections have resolved," The New York Times reports.
"This is exactly what you would hope for," University of Washington immunologist Marion Pepper, who authored one of the recent studies, told the Times. "All the pieces are there to have a totally protective immune response."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Especially encouraging, the Times explains, is evidence of immunity in patients who just had mild symptoms, which suggests, as University of California immunologist Smita Iyer explained, that "you can still get durable immunity without suffering the consequences of infection." Emory University immunologist Eun-Hyung Lee also told the Times, "Yes, you do develop immunity to this virus, and good immunity to this virus. That's the message we want to get out there."
At the same time, the Times notes that it's still not clear how long the immune responses might last, and the recent studies "do not demonstrate protection in action." Read more at The New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Road trip: New England’s maple syrup season
Feature New England is serving up maple syrup in delicious and unexpected ways
By The Week US Published
-
Music Reviews: Mdou Moctar, Panda Bear, and Tate McRae
Feature “Tears of Injustice,” “Sinister Grift,” and “So Close to What”
By The Week US Published
-
What's at stake in the Mahmoud Khalil deportation fight?
Talking Points Vague accusations and First Amendment concerns
By Joel Mathis, The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published